Scilex Holding (SCLX) Common Equity (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Common Equity of -$254.1 million for Q1 2026, down 20.14% year-over-year from -$318.1 million in Q1 2025, and down 22.28% quarter-over-quarter from -$207.8 million in Q4 2025.
Scilex Holding (SCLX) Common Equity (2020 - 2026) Analysis & Trends
Scilex Holding's Common Equity history runs 7 years deep, the most recent figure standing at -$254.1 million for Q1 2026.
- In Q1 2026, Common Equity fell 20.14% year-over-year to -$254.1 million; the TTM figure through Mar 2026 stood at -$254.1 million (down 20.14% YoY), while the FY2025 annual figure was -$207.8 million, down 7.86% from the prior year.
- Common Equity for Q1 2026 stood at -$254.1 million, down from -$207.8 million in the prior quarter.
- The five-year high for Common Equity was $36.2 million in Q4 2022, with the low at -$254.1 million in Q1 2026.
- The 5-year median for Common Equity is -$207.8 million (2025), against an average of -$170.7 million.
- Peak annual rise in Common Equity reached 116.19% in 2022, while the deepest fall reached 2906.36% in 2022.
- Scilex Holding's Common Equity stood at $36.2 million in 2022, then slumped by 577.22% to -$172.9 million in 2023, then declined by 11.39% to -$192.6 million in 2024, then dropped by 7.86% to -$207.8 million in 2025, then declined by 22.28% to -$254.1 million in 2026.
- Business Quant data shows SCLX's Common Equity at -$254.1 million in Q1 2026, -$207.8 million in Q4 2025, and -$179.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.21 Bn | 633.45 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 468.90 Bn | 462.33 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 378.18 Bn | 371.04 Bn | 12.21 Bn | 106.07 Bn |
| 4 | Novartis Ag | 302.34 Bn | 294.65 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.60 Bn | 252.70 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 236.39 Bn | 222.40 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 182.58 Bn | 179.41 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 161.17 Bn | 149.47 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Gsk | 105.37 Bn | 101.20 Bn | 8.24 Bn | 23.05 Bn |
| 10 | Scilex Holding | 39.97 Mn | -72.82 Mn | 3.97 Mn | -310.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -254.07 Mn |
| Dec 31, 2025 | -207.78 Mn |
| Sep 30, 2025 | -179.72 Mn |
| Jun 30, 2025 | -248.99 Mn |
| Mar 31, 2025 | -211.48 Mn |
| Dec 31, 2024 | -192.64 Mn |
| Sep 30, 2024 | -211.32 Mn |
| Jun 30, 2024 | -214.69 Mn |
| Mar 31, 2024 | -189.79 Mn |
| Dec 31, 2023 | -172.94 Mn |
| Sep 30, 2023 | -162.67 Mn |
| Jun 30, 2023 | 10.42 Mn |
| Mar 31, 2023 | 11.08 Mn |
| Dec 31, 2022 | 36.24 Mn |
| Sep 30, 2022 | -229.40 Mn |
| Jun 30, 2022 | -252.10 Mn |
| Mar 31, 2022 | -231.57 Mn |
| Dec 31, 2021 | -223.88 Mn |
| Sep 30, 2021 | -9.83 Mn |
| Jun 30, 2021 | -8.39 Mn |